BON on Nasdaq
Bon Natural Life Ltd
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with MediWound (Israel), Charlie's Holdings, Inc. or FITLIFE BRANDS, INC., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
20.8%Gross margin2
-8.7%Operating margin2
-10.7%Net margin2
-21.7%Revenue growth, 20252
-3.5%Return on equity2
0.01×Debt to equity2
$134.3KFree cash flow2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Fragrance Compounds brought in 43% of the revenue Bon Natural Life Ltd broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Fragrance Compounds | $14.3M | $4.9M | $8.1M |
| Bioactive Food Ingredients | $6.5M | $12.2M | $7.3M |
| Health Supplements (Solid Drinks) | $8.7M | $6.7M | $3.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue79¢$14.8M
- Research and development4¢$754.2K
- Other costs13¢$2.4M
- Interest2¢$366.2K
- Income tax2¢$339.4K
Out of $18.7M in revenue.2 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending5¢$6.8K
- Kept or used elsewhere95¢$134.3K
Out of $141.1K of cash from operations.2
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| REVENUE | $18.7M | $23.8M | $29.5M |
| COST OF REVENUE | -$14.8M | -$16.7M | -$20.7M |
| GROSS PROFIT | $3.9M | $7.1M | $8.8M |
| Selling expenses | -$436.9K | -$270.6K | -$293.7K |
| General and administrative expenses | -$4.3M | -$3.3M | -$2.3M |
| Research and development expenses | -$754.2K | -$1.6M | -$298.5K |
| TOTAL OPERATING EXPENSES | -$5.5M | -$5.2M | -$2.9M |
| (LOSS) INCOME FROM OPERATIONS | -$1.6M | $1.9M | $5.9M |
| Interest income | $867 | $393 | $9.4K |
| Interest expense | -$366.2K | -$303.3K | -$238.2K |
| Government subsidiaries | $37.3K | $63.5K | $25.4K |
| Gain (loss) on disposal of subsidiaries | $160.9K | ||
| Other income (expenses) | $80.3K | -$918.2K | -$160.3K |
| TOTL OTHER EXPENSES, NET | -$86.8K | -$1.2M | -$363.6K |
| INCOME BEFORE INCOME TAX PROVISION | -$1.7M | $715.9K | $5.6M |
| INCOME TAX PROVISION | $339.4K | $351.2K | $1.0M |
| NET (LOSS) INCOME FROM CONTINUING OPERATIONS | -$2.0M | $364.8K | $4.6M |
| Net loss from the sale of the Gansu subsidiary | -$19.5K | -$17.9K | |
| NET (LOSS) INCOME | -$2.0M | $345.2K | $4.6M |
| Less: net loss attributable to non-controlling interest | -$54.7K | -$52.9K | -$43.3K |
| NET (LOSS) INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED | -$2.0M | $398.2K | $4.6M |
| Total foreign currency translation adjustment | -$298.9K | $1.1M | -$1.0M |
| TOTAL COMPREHENSIVE (LOSS) INCOME | -$2.3M | $1.4M | $3.5M |
| Less: comprehensive loss attributable to non-controlling interest | -$55.4K | -$54.3K | -$33.3K |
| COMPREHENSIVE (LOSS) INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED | -$2.3M | $1.5M | $3.5M |
| Basic | -$0.72 | $4.17 | $125.72 |
| Diluted | -$0.72 | $4.14 | $124.92 |
| Basic | 2.8M shares | 95.5K shares | 36.6K shares |
| Diluted | 2.8M shares | 96.1K shares | 36.8K shares |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-09-30 | 2024-09-30 | 2024-02-29 |
|---|---|---|---|
| Cash | $500.0K | $80.5K | |
| Restricted cash | $2.5M | $576.7K | |
| Accounts receivable, net | $11.0M | $11.8M | |
| Inventories, net | $3.3M | $1.6M | |
| Advances to suppliers, net | $15.9M | $14.5M | |
| Due from related parties | $527.4K | $33.2K | |
| Prepaid expenses and other current assets | $8.7M | $4.3M | |
| Current assets held for sale associated with the sale of the Gansu subsidiary | $7.0M | ||
| TOTAL CURRENT ASSETS | $45.8M | $39.8M | |
| Property, plant and equipment, net | $18.2M | $15.0M | |
| Intangible assets, net | $6.4M | $777.0K | |
| Right-of-use lease assets, net | $113.2K | $141.9K | |
| Non-current other receivables | $14.7M | ||
| Deferred tax assets, net | $1.4K | ||
| Non-current assets held for sale associated with the sale of the Gansu subsidiary | $6.0M | ||
| TOTAL NON-CURRENT ASSETS | $39.4M | $22.0M | |
| TOTAL ASSETS | $85.2M | $61.8M | |
| Short-term loans | $10.2M | $5.7M | |
| Current portion of long-term loans | $1.1M | $461.8K | |
| Accounts payable | $7.6M | $3.4M | |
| Due to related parties | $134.1K | $244.9K | |
| Taxes payable | $4.9M | $3.7M | |
| Deferred revenue | $219.7K | $506.8K | |
| Accrued expenses and other current liabilities | $2.0M | $2.2M | |
| Operating lease liabilities, current | $76.8K | $148.9K | |
| Current liabilities held for sale associated with the sale of the Gansu subsidiary | $11.5K | ||
| TOTAL CURRENT LIABILITIES | $26.3M | $16.4M | |
| Long-term loans | $842.8K | $970.1K | |
| Operating lease liability, non-current | $36.6K | ||
| TOTAL NON-CURRENT LIABILITIES | $879.4K | $970.1K | |
| TOTAL LIABILITIES | $27.2M | $17.4M | |
| Additional paid-in capital | $40.8M | $25.0M | |
| Statutory reserve | $2.8M | $2.7M | |
| Retained earnings | $16.6M | $18.7M | |
| Accumulated other comprehensive (loss) | -$2.9M | -$2.6M | |
| TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS EQUITY | $57.6M | $43.9M | |
| NON-CONTROLLING INTEREST | $447.1K | $442.8K | |
| TOTAL SHAREHOLDERS EQUITY | $58.0M | $44.3M | |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | $85.2M | $61.8M | |
| Common stock, par value | $0.00 | ||
| Common stock, shares authorized | 270.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Net (loss) income | -$2.0M | $345.2K | $4.6M |
| Less: net loss from discontinued operations | -$19.5K | -$17.9K | |
| NET (LOSS) INCOME FROM CONTINUING OPERATIONS | -$2.0M | $364.8K | $4.6M |
| Allowance for doubutful accounts | $693.8K | $1.0M | |
| Depreciation and amortization | $1.1M | $1.1M | $949.5K |
| Inventory reserve (recovery) | $432.8K | -$990 | -$5.8K |
| Deferred income tax | $1.4K | ||
| Amortization of operating lease right-of-use assets | $198.4K | $170.2K | $228.6K |
| Share-based compensation | $1.4M | $1.3M | $349.4K |
| (Gain) loss on disposal of subsidiaries | -$160.9K | ||
| Accounts receivable | -$108.8K | -$6.8M | $2.1M |
| Inventories | -$2.2M | -$530.6K | $721.4K |
| Advance to supplies, net | -$1.7M | -$5.6M | -$4.6M |
| Prepaid expenses and other current assets | -$11.7M | -$7.4M | -$2.2M |
| Accounts payable | $6.1M | $1.9M | $833.5K |
| Operating lease liabilities | -$33.0K | -$232.1K | |
| Taxes payable | $1.3M | $832.5K | $1.6M |
| Deferred revenue | -$276.2K | $385.8K | -$80.2K |
| Accrued expenses and other current liabilities | $7.2M | $5.5M | $2.1M |
| Net cash provided by (used in) operating activities from continuing operations | $141.1K | -$7.7M | $6.3M |
| Net cash used in operating activities from discontinued operations | -$14.6K | -$7.0M | |
| Net cash provided by (used in) operating activities | $141.1K | -$7.7M | -$616.9K |
| Purchase of short-term investments | -$67 | ||
| Proceeds upon redemption of short-term investments | $65 | ||
| Purchase of property and equipment | -$6.8K | -$7.0K | -$61.9K |
| Capital expenditure on construction-in-progress | -$4.4M | ||
| Purchase of intangible assets | -$5.6M | -$669.2K | |
| Proceeds of borrowings to related parties | $5.6K | ||
| Net cash used in investing activities from continuing operations | -$10.0M | -$7.0K | -$725.5K |
| Net cash used in investing activities from discontinued operations | -$8.7K | -$460.1K | |
| Net cash used in investing activities | -$10.0M | -$15.7K | -$1.2M |
| Net proceeds from issuance of ordinary shares | $10.7M | $5.6M | $2.0M |
| Proceeds from short-term loans | $12.0M | $4.3M | $2.9M |
| Proceeds from long-term loans | $970.5K | $694.0K | $1.1M |
| Repayment of short-term loans | -$7.3M | -$1.5M | -$2.7M |
| Repayment of long-term loans | -$340.1K | -$451.3K | -$2.1M |
| Proceeds from (repayment of) borrowings from related parties | -$578.9K | $205.2K | $10.4K |
| Proceeds from (repayment of) third party loans | -$96.1K | ||
| Proceeds from (repayment of) finance lease | -$26.5K | ||
| Net cash provided by financing activities from continuing operations | $15.5M | $8.8M | $1.2M |
| Net cash provided by financing activities from discontinued operations | $5.0K | $3.1K | |
| Net cash provided by financing activities | $15.5M | $8.8M | $1.2M |
| Effect of changes of foreign exchange rates on cash | $7.4K | -$469.8K | -$80.8K |
| Net increase (decrease) in cash and restricted cash | $5.6M | $545.9K | -$728.1K |
| Cash paid for interest expenses | $324.0K | $303.3K | $238.2K |
| Cash paid for income taxes | $478.7K | ||
| Exercise of options | $2 | ||
| Unpaid purchase of property and equipment | $403.3K |
Recent filings
- Sep 23, 20266-K
- May 15, 20263
- Apr 23, 20263
- Apr 10, 20263
- Apr 10, 20263
- Apr 10, 20263
- Apr 10, 20263
- Apr 10, 20263
- Apr 10, 20263
- Mar 19, 20266-K
- Feb 17, 20266-K
- Jan 23, 202620-F
- Dec 10, 20256-K
- Nov 25, 20256-K
- Nov 14, 20256-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7